Experimental Alzheimer’s drug slows cognitive decline in late-stage study

Published



An experimental Alzheimer’s drug made by Eisai Co. and Biogen Inc. slowed the rate of cognitive decline among patients in the early stages of the illness in a large study, improving its chances of future approval.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.